New York-based Pfizer Inc. (PFE) is a global pharmaceutical and biotechnology company that develops, manufactures, and ...

A Pfizer joint venture in India that manufactures injectable chemotherapy drugs for U.S. cancer patients remains closed ...

Pfizer's dividend yield sits near 6%, but the company paid out more in dividends last year than it generated in free cash ...

Pfizer (NYSE:PFE) reported positive Phase 3 MagnetisMM-32 results for ELREXFIO in relapsed or refractory multiple myeloma.

Pfizer Inc. PFE on Tuesday released topline results from its Phase 3 MagnetisMM-32 study evaluating Elrexfio (elranatamab) as ...

In the Phase 3 MagnetisMM-32 trial, ELREXFIO demonstrated a clinically meaningful and statistically significant benefit for ...

Pfizer’s Elrexfio has taken another step on its path to potential commercial momentum: The drugmaker just announced another ...

Dividends keep paying whether you sell or not, and four healthcare giants quietly generate serious retirement income while ...

Pfizer’s Jeff Legos discusses how science, AI and patient insights are shaping cancer research and the next generation of ...

Pfizer is deeply unloved, and for good reason, but don't count this drug maker out just yet.

About TALZENNA® (talazoparib) TALZENNA is an oral inhibitor of poly ADP-ribose polymerase (PARP), which plays a role in DNA damage repair. Preclinical studies have demonstrated that TALZENNA blocks ...